{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T03:56:42Z","timestamp":1770436602562,"version":"3.49.0"},"reference-count":10,"publisher":"BMJ","content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Reports"],"accepted":{"date-parts":[[2014,4,18]]},"abstract":"<jats:p>Pure erythroid leukaemia is a rare subtype of acute myeloid leukaemia (AML) and its occurrence at acute lymphoblastic leukaemia (ALL) relapse has not been reported earlier. A 39-year-old man received chemotherapy for Philadelphia-negative B cell ALL. Subsequently, he developed pure erythroid leukaemia with &gt;80% immature erythroid precursors in bone marrow showing block positivity on periodic acid-Schiff stain, expressing CD71, CD34 but lacking CD235a. The interval between exposure to multidrug chemotherapy including cyclophosphamide and AML diagnosis was 2\u2005years and 9\u2005months. No cytogenetic abnormality was detected at the time of relapse. The patient died 2\u2005weeks after starting AML chemotherapy. The relatively narrow time interval (usually 5\u201310\u2005years) between chemotherapy and AML development and normal karyotype at relapse raises a possibility of lineage switch besides therapy-related AML as the likely pathogenesis. Further exploration of such cases may unravel the pathways responsible for lineage assignment in pluripotent stem cells.<\/jats:p>","DOI":"10.1136\/bcr-2013-201724","type":"journal-article","created":{"date-parts":[[2014,5,19]],"date-time":"2014-05-19T08:55:33Z","timestamp":1400489733000},"page":"bcr2013201724","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":4,"title":["Secondary pure erythroid leukaemia in relapsed acute lymphoblastic leukaemia: lineage switch or chemotherapy effect?"],"prefix":"10.1136","volume":"2014","author":[{"given":"Sanjeev Kumar","family":"Gupta","sequence":"first","affiliation":[{"name":"Laboratory Oncology Unit, Dr B.R.A. Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS), Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rajive","family":"Kumar","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit, Dr B.R.A. Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS), Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taher","family":"Chharchhodawala","sequence":"additional","affiliation":[{"name":"Laboratory Oncology Unit, Dr B.R.A. Institute Rotary Cancer Hospital (IRCH), All India Institute of Medical Sciences (AIIMS), Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lalit","family":"Kumar","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, All India Institute of Medical Sciences (AIIMS), Delhi, India"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2014,5,19]]},"reference":[{"key":"2025082702322446000_2014.may19_1.bcr2013201724.1","unstructured":"Arber DA Brunning RD Orazi A . Acute myeloid leukaemia, not otherwise specified. In: Swerdlow SH Campo E Harris NL ., eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon: IARC, 2008:130\u20139."},{"key":"2025082702322446000_2014.may19_1.bcr2013201724.2","doi-asserted-by":"publisher","DOI":"10.1155\/2012\/406796"},{"key":"2025082702322446000_2014.may19_1.bcr2013201724.3","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1182\/blood.V64.3.701.701","article-title":"Lineage switch in acute leukemia","volume":"64","author":"Stass","year":"1984","journal-title":"Blood"},{"key":"2025082702322446000_2014.may19_1.bcr2013201724.4","doi-asserted-by":"publisher","DOI":"10.3346\/jkms.2011.26.6.829"},{"key":"2025082702322446000_2014.may19_1.bcr2013201724.5","doi-asserted-by":"publisher","DOI":"10.3343\/kjlm.2007.27.2.102"},{"key":"2025082702322446000_2014.may19_1.bcr2013201724.6","doi-asserted-by":"publisher","DOI":"10.1007\/s10147-009-0007-3"},{"key":"2025082702322446000_2014.may19_1.bcr2013201724.7","doi-asserted-by":"publisher","DOI":"10.1038\/sj.leu.2402713"},{"key":"2025082702322446000_2014.may19_1.bcr2013201724.8","unstructured":"Jagasia MH . Complications of hematopoietic neoplasms. In: Greer JP Foerster J Rodgers GM . eds. Wintrobe's clinical hematology. 12th edn. Philadelphia: Lippincott Williams & Wilkins, 2009:1669\u201393."},{"key":"2025082702322446000_2014.may19_1.bcr2013201724.9","unstructured":"Vardiman JW Arber DA Brunning RD . Therapy-related myeloid neoplasms. In: Swerdlow SH Campo E Harris NL . eds. WHO classification of tumours of haematopoietic and lymphoid tissues. 4th edn. Lyon: IARC, 2008:127\u20139."},{"key":"2025082702322446000_2014.may19_1.bcr2013201724.10","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2002-11-3343"}],"updated-by":[{"DOI":"10.1136\/bcr-2013-201724corr1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2014,10,16]],"date-time":"2014-10-16T00:00:00Z","timestamp":1413417600000}}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2013-201724","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,27]],"date-time":"2025-08-27T09:32:33Z","timestamp":1756287153000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2013-201724"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,5,19]]},"references-count":10,"alternative-id":["10.1136\/bcr-2013-201724"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2013-201724","relation":{},"ISSN":["1757-790X"],"issn-type":[{"value":"1757-790X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2014,5,19]]}}}